Menu
About Us
Company Overview
Our Values
Board of Directors
Team
Scientific Advisers
Clinical Advisers
Corporate Directory
Corporate Governance
Pipeline
Clinical Trial
Investor Centre
Welcome
Investor Fact Sheet
ASX Announcements
Reports
Annual Reports
Half Yearly Reports
Quarterly Reports
Top 20 Shareholders
Research Reports
Shareholder Services
Investor FAQs
US Shareholders
Investor Newsletters
Communication
In the News
Presentations
Contact Us
Contact Us
Email Alerts
In the news
Recent Posts
Amplia completes recruitment of ACCENT Trial
New data for narmafotinib presented at International Conference
Positive New Data and Strong Recruitment in Pancreatic Cancer Trial
Amplia Enters into Preclinical Collaboration with Korean Specialist Drug Screening Company Next&Bio
Interim Data from ACCENT Pancreatic Cancer Trial
Dr Chris Burns elected as a Fellow to the Australian Academy of Health and Medical Sciences (AAHMS)
Categories
Archive
Company News
Investor Newsletters
Videos
11 Apr 2023
Dose Escalation Approved in ACCENT Clinical Trial of AMP945
Read More
28 Feb 2023
ACCENT Trial Recruitment Progress | Cohort 2 filled
Read More
13 Feb 2023
Women in Science | Q&A with Dr Terrie-Anne Cock, Head of Translational Biology
Read More
09 Feb 2023
35th Annual Lorne Cancer Conference, 9-11 February 2023
Read More
01 Feb 2023
First Patient Recruited to Cohort 2 of ACCENT Trial in Pancreatic Cancer
Read More
08 Dec 2022
Meet the CEO | Dr Chris Burns
Read More
29 Nov 2022
ACCENT Trial Recruitment Progress
Read More
03 Oct 2022
AMP886 Activity in Acute Myeloid Leukemia (AML)
Read More
18 Aug 2022
MEDIA RELEASE | Australian-made treatment for pancreatic cancer – clinical trial milestone
Read More
02 Aug 2022
First patient recruited into ACCENT trial
Read More
28 Jul 2022
QUARTERLY REPORT & 4C
Read More
23 Jun 2022
Navigating human research ethics
Read More
19 Apr 2022
QUARTERLY ACTIVITIES REPORT & 4C
Read More
30 Mar 2022
Amplia is hiring
Read More
17 Feb 2022
Improving Pancreatic Cancer Survival Rates
Read More
11 Feb 2022
WOMEN IN SCIENCE | Rhiannon Jones, Director, Operations
Read More
24 Jan 2022
Quarterly Report & 4C
Read More
02 Dec 2021
$2.1M R&D Cash Flow Loan
Read More
17 Nov 2021
New Phase 1 Clinical Trial Data
Read More
08 Nov 2021
$12.4m Capital Raise
Read More
1
2
3
4
